Imagine caffeine, without the crash.

Lennham has discovered that selective deuteration of caffeine can significantly extend its half-life.

We have demonstrated these results in both human and rat studies. Rats showed an 80% increase in exposure vs. an equivalent dose of caffeine, with similar peak exposures (CMax).

The results from the human PK study are even more dramatic and are pending publication. The data below were presented at ISSN 2021.

Arithmetic mean plasma concentration over 48 hours following single dose administration of 50 mg caffeine and molar equivalent of d9-caffeine

Arithmetic mean plasma concentration over 48 hours following single dose administration of 50 mg caffeine and molar equivalent of d9-caffeine

Pharmacokinetic parameters and relative disposition of d9-caffeine, caffeine, and their respective major metabolites following administration of 50 mg caffeine or a molar equivalent of d9-caffeine

Pharmacokinetic parameters and relative disposition of d9-caffeine, caffeine, and their respective major metabolites following administration of 50 mg caffeine or a molar equivalent of d9-caffeine

d-Caffeine has broad potential as a food ingredient.

We are actively pursuing a Generally Recognized As Safe (GRAS) designation to support use as a food & beverage ingredient.

 

Lennham holds broad patents covering food & beverage applications of d-caffeine.

U.S. Patent No. 10,765,130

U.S. Patent No. 10,582,716

Additional pharmaceutical and nutraceutical patents are pending.